Socio-Economic Implications for the UK The potential for retatrutide to reduce the prevalence of obesity-related conditionssuch as the 42 identified conditions including cancer, cardiovascular disease, and strokecould lead to significant savings for the UK economy
Others may need a slower titration, a dose adjustment, or a discussion about long-term medication strategy
Rare but serious risks include pancreatitis and gallbladder issues
Patients and healthcare professionals are encouraged to report any suspected adverse reactions to the MHRA Yellow Card Scheme (available at yellowcard.mhra.gov.uk)
This brief aims to highlight how patent abuse is a key tool enabling the pharmaceutical industry to carry out its financialized business model that perpetuates structural health inequities, particularly among communities of color
Sharma used a large research network database and found that patients on GLP-1 agonists were 66% more likely to be diagnosed with gastroparesis than those not on the medication